← Leaderboards
Jose L. Lopez-Ribot
University Of Texas San Antonio
$7,729,701
Attributed
$9,658,580
Total exposure
14
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2006–25$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,086,580 · 15
By mechanism
U19$6,006,437 · 2
R01$5,046,171 · 3
R21$1,925,127 · 5
R33$1,332,370 · 1
R03$293,000 · 2
T32$281,025 · 1
Top collaborators
- Stanton Furst Mchardy5 shared
- Chiung-Yu Hung4 shared
- Floyd L. Wormley4 shared
- Astrid E Cardona2 shared
- Ambika Mathur2 shared
Most similar at University Of Texas San Antonio
Same institution · by research overlap
- Floyd L. Wormley$7,201,544
- Chiung-Yu Hung$5,101,104
- Thomas F. Patterson$4,803,300
Others in their field
Top investigators on “Candida Albicans”
- Alexander D Johnson · University Of California San Francisco$23,545,370
- Aaron P Mitchell · La Biomed Res Inst/ Harbor Ucla Med Ctr$20,872,115
- Gavin J Sherlock · Stanford University$18,218,461
- Jay B Jackson · Johns Hopkins University$17,529,470
- Scott G Filler · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center$14,524,347
- Gerald R Fink · Whitehead Institute For Biomedical Res$14,278,186
Research focus
Candida AlbicansCandidiasisInfectionPharmaceutical PreparationsAntifungal AgentsResistanceAntifungal TherapyIn VitroMycosesMorbidity - Disease RateFungusIn VivoResearch PersonnelDrug DevelopmentToxic EffectLeadHealth Care CostsImmuneMicrobial BiofilmsGrowthSurfaceMedicalLaboratoriesCells
Grant awards (43)
SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.$1,357,000
U19 · FY2025 · AI
BSL3 Drug Screening Core$271,400
U19 · FY2025 · AI · contact PI
MMI-T32 Training Pre-doctoral Scientists in Molecular Microbiology and Immunology at UTSA$138,426
T32 · FY2025 · AI
SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.$1,357,000
U19 · FY2024 · AI
MMI-T32 Training Pre-doctoral Scientists in Molecular Microbiology and Immunology at UTSA$142,599
T32 · FY2024 · AI
BSL3 Drug Screening Core$99,580
U19 · FY2024 · AI · contact PI
SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.$1,357,000
U19 · FY2023 · AI
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates$444,415
R33 · FY2023 · AI · contact PI
BSL3 Drug Screening Core$109,121
U19 · FY2023 · AI · contact PI
SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.$1,357,000
U19 · FY2022 · AI
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates$444,415
R33 · FY2022 · AI · contact PI
High Throughput Screening of Medicines for Malaria Ventures Chemical Libraries to Identify Novel Inhibitors of Candida auris$225,000
R21 · FY2022 · AI · contact PI
BSL3 Drug Screening Core$98,336
U19 · FY2022 · AI · contact PI
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates$443,540
R33 · FY2021 · AI · contact PI
High Throughput Screening of Medicines for Malaria Ventures Chemical Libraries to Identify Novel Inhibitors of Candida auris$187,500
R21 · FY2021 · AI · contact PI
Development of novel chemical series of Candida albicans biofilm inhibitors$367,500
R01 · FY2019 · AI · contact PI
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates$313,188
R21 · FY2019 · AI · contact PI
Development of novel chemical series of Candida albicans biofilm inhibitors$367,500
R01 · FY2018 · AI · contact PI
Development of novel chemical series of Candida albicans biofilm inhibitors$367,500
R01 · FY2017 · AI · contact PI
Targeting virulence against oral candidiasis in HIV/AIDS$367,500
R01 · FY2017 · DE · contact PI
Targeting virulence against oral candidiasis in HIV/AIDS$367,500
R01 · FY2016 · DE · contact PI
Development of novel chemical series of Candida albicans biofilm inhibitors$367,500
R01 · FY2016 · AI · contact PI
Development of novel chemical series of Candida albicans biofilm inhibitors$367,500
R01 · FY2015 · AI · contact PI
Targeting virulence against oral candidiasis in HIV/AIDS$367,500
R01 · FY2015 · DE · contact PI
Targeting virulence against oral candidiasis in HIV/AIDS$367,500
R01 · FY2014 · DE · contact PI
Development of Monoclonal Antibody (Mab) Biologics against Neonatal Candidiasis$73,500
R03 · FY2014 · AI · contact PI
Targeting virulence against oral candidiasis in HIV/AIDS$367,500
R01 · FY2013 · DE · contact PI
Development of Monoclonal Antibody (Mab) Biologics against Neonatal Candidiasis$73,500
R03 · FY2013 · AI · contact PI
Candida albicans biofilm dispersion as a key step during candidiasis$180,625
R21 · FY2010 · AI · contact PI
Host Immunity and Virulence in Candida albicans Pathogenesis$336,965
R01 · FY2009 · AI · contact PI
Candida albicans biofilm dispersion as a key step during candidiasis$216,750
R21 · FY2009 · AI · contact PI
Host Immunity and Virulence in Candida albicans Pathogenesis$336,965
R01 · FY2008 · AI · contact PI
Small molecule inhibitors of Candida albicans biofilm formation$169,681
R21 · FY2008 · DE · contact PI
Host Immunity and Virulence in Candida albicans Pathogenesis$343,491
R01 · FY2007 · AI · contact PI
Small molecule inhibitors of Candida albicans biofilm formation$205,883
R21 · FY2007 · DE · contact PI
Host Immunity and Virulence in Candida albicans Pathogenesis$353,750
R01 · FY2006 · AI · contact PI
Analysis of the Candida Albicans Proteome$145,333
R21 · FY2004 · DE
Analysis of the Candida Albicans Proteome$73,667
R21 · FY2004 · DE
NRG1 Regulation of Candida albicans Virulence$73,000
R03 · FY2004 · AI
Analysis of the Candida Albicans Proteome$207,500
R21 · FY2003 · DE
NRG1 Regulation of Candida albicans Virulence$73,000
R03 · FY2003 · AI
PROTECTIVE ANTIBODIES TO CANDIDA ALBICANS MP58$102,443
R29 · FY2001 · AI
PROTECTIVE ANTIBODIES TO CANDIDA ALBICANS MP58$100,007
R29 · FY2000 · AI